In addition, Ma et al.’s work has shown that the MAPK/ERK signaling pathway is involved in the HMGB3-mediated malignant progression of ovarian cancer [142], and inhibition of MAPK/ERK signaling counteracts the effect of high HMGB3 expression in ovarian cancer. The gene discussed is HMGB3; the disease is ovarian cancer.